Applicant, as named in the Orange Book
Viiv Hlthcare
Next listed expiry: Rukobia on 13 Jul 2029. 10 products with live protection, 8 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Rukobia NDA 212950 fostemsavir tromethamine | 13 Jul 2029 patent |
| Tivicay NDA 204790 dolutegravir sodium | 8 Jun 2030 patent |
| Tivicay Pd NDA 213983 dolutegravir sodium | 8 Jun 2030 patent |
| Triumeq NDA 205551 abacavir sulfate; dolutegravir sodium; lamivudine | 8 Jun 2030 patent |
| Triumeq Pd NDA 215413 abacavir sulfate; dolutegravir sodium; lamivudine | 8 Jun 2030 patent |
| Dovato NDA 211994 dolutegravir sodium; lamivudine | 24 Jan 2031 patent |
| Vocabria NDA 212887 cabotegravir sodium | 4 Feb 2031 patent |
| Apretude NDA 215499 cabotegravir | 15 Sep 2031 patent |
| Juluca NDA 210192 dolutegravir sodium; rilpivirine hydrochloride | 5 Sep 2038 patent |
| Cabenuva Kit NDA 212888 · 2 strengths cabotegravir; rilpivirine | 1 Oct 2040 patent, carve-out possible |
Recent events
- Selzentry · Generic approved · ANDA 216143, Rhodes PharmsApproved 4 Nov 2025Detected 25 Oct 2026
- Triumeq · Exclusivity expires within 90 days PEDExclusivity expires 15 Dec 2026Detected 24 Oct 2026
- Triumeq Pd · Exclusivity expires within 90 days PEDExclusivity expires 15 Dec 2026Detected 24 Oct 2026
Products without listed protection (8)
| Drug | Earliest generic entry |
|---|---|
| Epivir NDA 020596 lamivudine | open now no listed protection |
| Epivir NDA 020564 · 2 strengths lamivudine | open now no listed protection |
| Retrovir NDA 019951 zidovudine | open now no listed protection |
| Retrovir NDA 019910 zidovudine | open now no listed protection |
| Retrovir NDA 019655 zidovudine | open now no listed protection |
| Selzentry NDA 208984 maraviroc | open now no listed protection |
| Selzentry NDA 022128 · 2 strengths maraviroc | open now no listed protection |
| Ziagen NDA 020978 abacavir sulfate | open now no listed protection |